Vidarabine monohydrate
Based on 8 publication(s) in Google Scholar
Vidarabine monohydrate is a Purine nucleoside derivative and Antiviral agent. The triphosphate derivative of Vidarabine monohydrate competitively inhibits DNA polymerase, incorporates into the terminus of elongating DNA molecules, and interferes with the early steps of viral DNA synthesis. Vidarabine monohydrate inhibits the replication of herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus and vaccinia virus, reduces viral shedding, and accelerates skin healing. Vidarabine monohydrate is metabolized to arabinosyl hypoxanthine, causes minimal impairment of corneal wound healing in rabbit models, and is associated with recurrence of herpes simplex encephalitis. Vidarabine monohydrate can be used in the research of herpetic keratoconjunctivitis, herpes simplex encephalitis, herpetic uveitis, and chronic active hepatitis associated with hepatitis B virus.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.99%
- CAS No.: 24356-66-9
- 화학식: C10H15N5O5
- 분자량:285.26
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Glycoside Compound Library
HY-L042
-
Nucleotide Compound Library
HY-L044
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Off-patent Drug Library
HY-L141
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
MCE Kinase Hinge Binder Fragment Library
HY-L907
Publications Citing Use of MedChemExpress (MCE) Vidarabine monohydrate
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Cells. 2022 Oct 11;11(20):3187. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Cell Signal. 2026 Aug:144:112537. [Abstract]
- J Cell Physiol. 2021 Aug;236(8):5785-5800. [Abstract]
- Int J Biochem Cell Biol. 2022 Aug:149:106247. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- bioRxiv. 2020 Apr.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Vidarabine monohydrate inhibits herpes simplex virus, varicella-zoster virus, and cytomegalovirus in in vitro cell culture systems[1].
Vidarabine monohydrate exerts its antiviral effect via phosphorylation to a triphosphate derivative that competitively inhibits DNA polymerase and is incorporated into terminal positions of growing DNA molecules[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:unspecified strain[1]
-
Dosage:3%
-
Administration:topical to the eye; four times daily
-
Result:Achieved complete healing of 5 mm corneal lesions by 60 hours, with no significant difference in healing rate compared to placebo or idoxuridine.
Achieved complete healing of 10 mm corneal lesions by 8 days, with no significant difference in healing rate compared to placebo or idoxuridine.
Showed significantly better regenerated epithelium quality (lower scores) than idoxuridine-treated eyes on days 4 and 7 (p = 0.05), with results comparable to placebo.
Demonstrated less severe histological abnormalities compared to idoxuridine-treated eyes.
Chemical Information
-
CAS No. 24356-66-9
-
Appearance Solid
-
분자량 285.26
-
화학식 C10H15N5O5
-
Color White to off-white
-
SMILES
O[C@H]1[C@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O[C@@H]1CO.O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Cells
2022 Oct 11;11(20):3187. PMID: 36291055 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Cell Signal
TP53 links mitochondria-endoplasmic reticulum crosstalk and ferroptosis in septic cardiomyopathy: Protective modulation by nicorandil. [Abstract]2026 Aug:144:112537. PMID: 41997516 -
J Cell Physiol
C1q/tumor necrosis factor-related protein-6 attenuates TNF-α-induced apoptosis in salivary acinar cells via AMPK/SIRT1-modulated miR-34a-5p expression. [Abstract]2021 Aug;236(8):5785-5800. PMID: 33400820 -
Int J Biochem Cell Biol
C1q/tumour necrosis factor-related protein-3 alleviates high-glucose-induced lipid accumulation and necroinflammation in renal tubular cells by activating the adenosine monophosphate-activated protein kinase pathway. [Abstract]2022 Aug:149:106247. PMID: 35753650 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
용액&용해도
DMSO : 250 mg/mL (876.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (281 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Whitley R, et al. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 1980 Oct;20(4):267-82. [Content Brief]
[2]. VanLandingham KE, et al. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA. 1988;259(7):1051-1053. [Content Brief]
[3]. Stolk LM, et al. Formulation of a stable vidarabine infusion fluid. Pharm Weekbl Sci. 1983;5(2):57-60. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5056 mL | 17.5279 mL | 35.0557 mL | 87.6393 mL |
| 5 mM | 0.7011 mL | 3.5056 mL | 7.0111 mL | 17.5279 mL | |
| 10 mM | 0.3506 mL | 1.7528 mL | 3.5056 mL | 8.7639 mL | |
| 15 mM | 0.2337 mL | 1.1685 mL | 2.3370 mL | 5.8426 mL | |
| 20 mM | 0.1753 mL | 0.8764 mL | 1.7528 mL | 4.3820 mL | |
| 25 mM | 0.1402 mL | 0.7011 mL | 1.4022 mL | 3.5056 mL | |
| 30 mM | 0.1169 mL | 0.5843 mL | 1.1685 mL | 2.9213 mL | |
| 40 mM | 0.0876 mL | 0.4382 mL | 0.8764 mL | 2.1910 mL | |
| 50 mM | 0.0701 mL | 0.3506 mL | 0.7011 mL | 1.7528 mL | |
| 60 mM | 0.0584 mL | 0.2921 mL | 0.5843 mL | 1.4607 mL | |
| 80 mM | 0.0438 mL | 0.2191 mL | 0.4382 mL | 1.0955 mL | |
| 100 mM | 0.0351 mL | 0.1753 mL | 0.3506 mL | 0.8764 mL |
Vidarabine monohydrate Related Classifications
HY-N6666 Related Classifications
Powered by Bioz